Parity and NIS Expression in Atypical Cells of Triple-Negative Breast Cancer, and Prognosis
Authors:
- Grigory DemyashkinGDGrigory Demyashkin
- Eugenia KoganEKEugenia Kogan
- Tatiana DemuraTDTatiana Demura
- Anastasia GuzikAGAnastasia Guzik
- Dmitriy BelokopytovDBDmitriy Belokopytov
- Maxim BatovMBMaxim Batov
- Vladimir ShchekinVSVladimir Shchekin
- Irina BicherovaIBIrina Bicherova
- Petr ShegaiPSPetr Shegai
- Andrei KaprinAKAndrei Kaprin
Open Access
- 13 October 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9947
Abstract
Breast cancer is one of the most common malignancies worldwide, affecting 2.3 million and causing 670,000 deaths in women annually. However, data indicate that the risk of developing breast cancer decreases with pregnancy at a young age, and each subsequent pregnancy further reduces the risk by approximately 10%. One of the characteristics inherent in both the mammary gland epithelium in pregnant women and luminal epithelial adenocarcinomas is the increased expression of NIS—the sodium/iodide symporter, whose defective cytoplasmic forms possess pro-oncogenic properties. Therefore, the analysis of the degree of influence of pregnancy on NIS expression in breast cancer cells is of medical interest. The aim of this study is to conduct a comparative morphological analysis of NIS expression in breast cancer cells according to the number of pregnancies of each patient. This study included 161 patients with triple-negative breast cancer who visited the P.A. Herzen Moscow Oncology Research Institute from 2020 to 2023. Immunohistochemical examination was performed using antibodies to NIS. The gravidity status of women was determined based on provided medical documentation. The degree of NIS expression was assessed using a modified Gainor scale. Statistical analysis was performed using mean and standard deviation (SD) depending on the normality of the distribution (Lilliefors test: p > 0.20); a p-value ≤ 0.05 was considered statistically significant. The degree of correlation between variables was assessed using Kendall’s tau rank correlation coefficient. A weak to moderate negative correlation (τ: −0.369) was found between the number of pregnancies and the degree of NIS expression in triple-negative breast cancer cells. In patients with triple-negative breast cancer, a weak to moderate negative correlation was found between the degree of NIS expression and gravidity status. The discovered phenomenon is likely due to the terminal differentiation of the mammary gland epithelium that occurs during pregnancy. This may potentially indicate the suppression of pro-oncogenic properties of atypical cells developed from the epithelium that has undergone terminal differentiation.Keywords
This publication has 23 references indexed in Scilit:
- Time-varying effects of FOXA1 on breast cancer prognosisBreast Cancer Research and Treatment, 2021
- FOXA1 Regulation Turns Benzamide HDACi Treatment Effect-Specific in BC, Promoting NIS Gene-Mediated Targeted Radioiodine TherapyMolecular Therapy-Oncolytics, 2020
- Pregnancy reprograms the epigenome of mammary epithelial cells and blocks the development of premalignant lesionsNature Communications, 2020
- Pregnancy and Breast Cancer: Pathways to Understand Risk and PreventionTrends in Molecular Medicine, 2019
- Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkersBritish Journal of Cancer, 2018
- FOXA1 hypermethylation: link between parity and ER-negative breast cancer in African American women?Breast Cancer Research and Treatment, 2017
- Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancerBreast Cancer Research and Treatment, 2017
- Sodium Iodide Symporter Expression in Adenoid Cystic Carcinoma of the Head and NeckJAMA Otolaryngology–Head & Neck Surgery, 2015
- Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer?Breast Cancer Research and Treatment, 2008
- The mammary gland iodide transporter is expressed during lactation and in breast cancerNature Medicine, 2000